Donate now and support the development of cure for ASPS

We are opening iCureASPS annual fundraiser with the traditional PMC bike ride. Our ASPS team rides yesterday and today for the 10th year at the Pan-Massachusetts Challenge (PMC). Ten years have passed since we founded our group and started to look for a cure for Alveolar Soft Part Sarcoma (ASPS), a rare cancer that has no cure and affects mainly young people.

The PMC is a bike-a-thon that crosses Massachusetts to raise money for cancer research and clinical trials at the Dana-Farber Cancer Institute in Boston. Members in our team ride this year 50, 90 or 140 miles between Wellesley to Cape Cod. Team ASPS set-up a restricted fund within the PMC. This restricted fund is aimed to achieve breakthrough in research and cure for Alveolar Soft Part Sarcoma.

Our goal this year is to initiate a new human clinical trial for ASPS patients in 2014 and WE NEED YOUR SUPPORT.

Team ASPS and iCureASPS already demonstrated that collaboration with the Dana Farber Cancer Institute is fruitful. Our collaboration resulted at the first ASPS clinical trial in 2005. This was the GVAX cancer vaccine clinical trial, which is under development by Dr. Glenn Dranoff.

Currently we are collaborating also with Dr. George Demetri, Dr. Andrew Wagner, Dr. Massimo Loda and Dr. Ewa Sicinska.

We hope to announce in 2014 the availability of a new clinical trial using a novel anti-cancer therapy.

There are two convenient ways to donate:
1. Online donations through the PMC website: Please click on the following link: Yosef Landesman ride page on the PMC website: (http://www.pmc.org/profile/YL0002). Then, once you are on my personal page, click on “DONATE TO MY RIDE”.

2. You can write a check payable to “PMC-Team ASPS YL0002”. Mail the check to:
Yosef Landesman
260 Tappan St.
Brookline, MA 02445

Your donation is a fully tax refundable. The PMC tax ID is 04-2746912
From the bottom of my heart I thank you for your support.

Best Wishes,
Yosef Landesman
______________________________________________________

Yosef Landesman, Ph.D.
President & Cancer Research Director
Cure Alveolar Soft Part Sarcoma International (iCureASPS)
e-mail: landesmany@yahoo.com

A Summary of Phase II Cederanib Clinical Trial

The summary of the phase 2 clinical trial of Cediranib on Alveolar Soft Part Sarcoma was recently published in the “Journal of Clinical Oncology” by Shivaani Kummar and others from the National Cancer Institute and the Frederick National Laboratory for Cancer Research.

The authors report that Cediranib has substantial single-agent activity, producing an objective response rate of 35% and a disease control rate of 84% at 24 weeks of treatment. On the basis of these results, they report on the opening of an “open-label, multicenter, randomized” phase II registration trial for patients with metastatic ASPS comparing Cediranib with Sunitinib, which is another VEGFR inhibitor. 

Below is the abstract from this important scientific publication: 

Purpose

Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor, for which no effective standard systemic treatment exists for patients with unresectable disease. Cediranib is a potent, oral small-molecule inhibitor of all three vascular endothelial growth factor receptors (VEGFRs). 

Patients and Methods

We conducted a phase II trial of once-daily cediranib (30 mg) given in 28-day cycles for patients with metastatic, unresectable ASPS to determine the objective response rate (ORR). We also compared gene expression profiles in pre- and post-treatment tumor biopsies and evaluated the effect of cediranib on tumor proliferation and angiogenesis using positron emission tomography and dynamic contrast-enhanced magnetic resonance imaging. 

Results

Of 46 patients enrolled, 43 were evaluable for response at the time of analysis. The ORR was 35%, with 15 of 43 patients achieving a partial response. Twenty-six patients (60%) had stable disease as the best response, with a disease control rate (partial response + stable disease) at 24 weeks of 84%. Microarray analysis with validation by quantitative real-time polymerase chain reaction on paired tumor biopsies from eight patients demonstrated downregulation of genes related to vasculogenesis. 

Conclusion

In this largest prospective trial to date of systemic therapy for metastatic ASPS, we observed that cediranib has substantial single-agent activity, producing an ORR of 35%

Click here to download the full publication.

______________________________________________________

Yosef Landesman, Ph.D.
President & Cancer Research Director
Cure Alveolar Soft Part Sarcoma International (iCureASPS)
e-mail: landesmany@yahoo.com

The 9th PMC bike ride of “Team ASPS”: More donations for preclinical studies of Alveolar Soft Part Sarcoma

On the first weekend of August 2012, “Team ASPS” participated for the 9th time in the Pan-Massachusetts Challenge (PMC) bike ride. This bike-a-thon crosses Massachusetts to raise money for cancer research and treatment at the Dana-Farber Cancer Institute (DFCI) in Boston. Our team rode 90 miles and raised $30,705 specifically dedicated for finding a cure for ASPS.

Donation this year will specifically support preclinical testing of novel drugs for the cure of ASPS.
Dr. George Demetri, Dr. Andrew Wagner, Dr. Massimo Loda and Dr. Ewa Sicinska at the Dana Farber Cancer Institute in Boston conduct those preclinical studies and reserach.

I will continue to update you here on this website on the results of those efforts that were initiated almost 10 years ago.

Cure ASPS International thanks “Team ASPS”, our donors and to the ASPS community for all the relentless support for our efforts to find a cure for ASPS.

Below are Photos taken during the 2012 PMC bike ride. Best wishes for a Happy New Year!

4_PMC12.JPG 3_PMC12.JPG 2_PMC12.JPG 1_PMC12.JPG
______________________________________________________

Yosef Landesman, Ph.D.
President & Cancer Research Director
Cure Alveolar Soft Part Sarcoma International (iCureASPS)
e-mail: landesmany@yahoo.com

In Honor of Patti Spires 1967-2012

Patti1.jpg

Patti Spires Hamilton was born at Ft. Meade, Maryland, on September 3, 1967, and passed away in Houston, TX on August 20, 2012. Her life was cut short by Alveolar Soft Part Sarcoma (ASPS), unfortunately undetected and unrecognized by the physicians who treated her for various other “ailments” during the past several years.

Patti was a beloved wife, mother, daughter, and friend. She was full of life and love. Patti offered understanding, compassion, and the gift of friendship to everyone she met.

She also loved people. To know Patti was to know her heart for relationships. She never dismissed someone because she thought them too insignificant, or because she was too consumed with her own life and schedule. She offered real compassion in an all too often uncompassionate world.

At the end of her life, she expressed her compassion – and developed a passion – for other ASPS sufferers by wanting to help with awareness, and finding a cure. While she was not granted a chance to fight ASPS in her own body, Patti hoped that her case would shed more light on the darkness surrounding this as of yet obscure, and largely unknown disease.

Patti leaves behind her husband Houston Hamilton Jr., four children: Brianne Burleson, Blake Burleson, Lauren Hamilton and Taylor Hamilton, and parents Jerry and Trixi Spires, as well as loving extended family and friends who miss her very much.

The ASPS community is sending condolences to Patti’s family and friends, and hope for a soon to come cure for ASPS.

Support the annual fundraiser of Team ASPS riding for the 9th year the Pan-Massachusetts Challenge (PMC)

Dear Alveolar Soft Part Sarcoma Community

This weekend, August 4-5th 2012, Team ASPS will ride for the 9th time the Pan-Massachusetts Challenge (PMC).

The PMC is a bike-a-thon that crosses Massachusetts to raise money for cancer research and clinical trials at the Dana-Farber Cancer Institute in Boston. As in previous years, I am asking you to sponsor our 90-150 miles bike ride from Wellesley to Bourne. Your donation will specifically support preclinical testing of novel drugs for the cure of ASPS. The study is conducted by Dr. George Demetri, Dr. Andrew Wagner, Dr. Massimo Loda and Dr. Ewa Sicinska.

Alveolar Soft Part Sarcoma (ASPS) is a rare cancer that has no cure.

For the last 9 years iCureASPS organization is working relentlessly to find a cure for ASPS. We aim to bring together ASPS patients, families and friends from all over the world in a shared interest to find a cure.  We support basic research aimed at understanding the underlying biology of this disease as well as projects that promote new and relevant therapeutic options. We support these through funding and by coordinating the successful transport of ASPS tumors for research.  Our website serves as a platform that provides updated information about the research and therapies for ASPS patients. An interactive “Forum” in the website enables ASPS patients to share experiences and receive information and group support from the ASPS community. It is through this knowledge that patients all over the world can make better decisions regarding their ASPS treatments.

Our organization works closely with the Dana-Farber Cancer Institute as well as with other institutions. With the help of friends and family who rode with me in our PMC “Team ASPS”, in the past 8 years, we raised and transferred over $300,000 exclusively for ASPS research programs. Thanks to those efforts, the first “Cancer Vaccine” Clinical Trial (GVAX) to treat ASPS was opened in January 2005. This clinical trial was followed by the ARQ197 clinical trial and now by the Cediranib clinical trial. 

There are two convenient ways to donate:

1.  Online donations through the PMC website: Please click on the following link: Yosef Landesman ride page on the PMC website: (http://www.pmc.org/profile/YL0002 ). Then, once you are on my personal page, click on “DONATE TO MY RIDE”.

2.   You can write a check payable to “PMC-Team ASPS YL0002”.  Mail the check to:

Yosef Landesman

260 Tappan St.

Brookline, MA 02445

Your donation is a fully tax refundable. The PMC tax ID is 04-2746912

I thank you for your support.

Best Wishes,

Yosef Landesman
  ______________________________________________________

Yosef Landesman, Ph.D.
President & Cancer Research Director
Cure Alveolar Soft Part Sarcoma International (iCureASPS)
e-mail: landesmany@yahoo.com

Update on the Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

If you consider to join the following clinical trial: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma ; study NCT01391962

Please note that patients can join only if:

·        Patients show evidence of disease progression

·        Patients must not have received prior treatment with any VEGF receptor tyrosine kinase inhibitor (e.g., cediranib, sunitinib, pazopanib, sorafenib); however, pre-treatment with bevacizumab is allowed.

Please also note that

·        Patients in this trial will be randomized to receive cediranib (30 mg) or sunitinib malate (37.5 mg) orally, once a day in 28-day cycles.

·        If and when disease progression is seen, then patients will cross over to the other treatment arm after a 2-week wash-out period.

Contacts

Deborah E Allen, R.N.                 (301) 402-5640                 allendeb@mail.nih.gov

Shivaani Kummar, M.D.               (301) 496-4916                 kummars@mail.nih.gov

  

Locations in the United States:

1.   California Santa Monica Oncology Center

Santa Monica, California, United States, 90403

2.    Maryland, National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, United States, 20892

Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office:     (888) NCI-1937

3.   Massachusetts, Dana Farber Cancer Institute

Boston, Massachusetts, United States, 02115

4.   New York, Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10021

5.   Texas, MD Anderson Cancer Center

Houston, Texas, United States, 77030-4096

We hope that the study will be conclusive and finally the first effective therapy for ASPS will be validated and then be available for all ASPS patients.

Best Wishes,
Yosef Landesman
______________________________________________________

Yosef Landesman, Ph.D.
President & Cancer Research Director
Cure Alveolar Soft Part Sarcoma International (iCureASPS)
e-mail: landesmany@yahoo.com

Important Update on Cediranib development for Alveolar Soft Part Sarcoma (ASPS)

Dear ASPS community. Many of our patients who participated in Cediranib clinical trials reported on our FORUM positive ASPS response to the drug. The conclusion that Cediranib shows favorable activity in ASPS is detailed in a summary of a Phase 2 clinical trial by Dr. Kummar in the 2011 meeting of the American Society of Clinical Oncology (ASCO). According to this study that included 36 ASPS patients, “Cediranib has substantial single-agent activity in ASPS, with a > 40% response rate and a disease control rate of 78%”. Those are very exciting news for us as so far no other drug showed efficacy in ASPS.

However, recently we learned that AstraZeneca, the developer of Cediranib has decided to transfer the development of Cediranib to the National Cancer Institute (NCI). AstraZeneca transferred 100 kg of Cediranib to the NCI for that purpose and the NCI opened a new Phase 2 clinical trial for ASPS patients. The goal of the new NCI trial is to confirm the early Phase 2 results and to compare Cediranib to Sunitinib, another drug that was tested on 9 ASPS patients at the Istituto Nazionale Tumori, Milan, Italy. The Sunitinib study showed partial response in 5 of the 9 ASPS patients.

The good news are that there is a possibility that one of the drugs will be selected and then be available for ASPS patients.

The new Cediranib and Sunitinib Phase 2 clinical trial is now open in California: Santa Monica Oncology Center, Maryland: NIH/NCI Bethesda, Massachusetts: Dana Farber and Texas: MD Anderson.

The NCI is making efforts to make sure that the study will be conclusive. Therefore travel and additional support will be given to every ASPS patient who participates in the trial in the NCI. The NCI will accept and pay travel also for ASPS patients who are not US residents. NonUS residents need to arrive to any US port and then their flight to the NCI, their treatment and minimal stay will be paid by the NCI!

For full details please click and read the details in the following link: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma. For more information, contact the NCI Referral Office at 1-888-NCI-1937, the study number is: NCT01391962.

We hope that the study will be conclusive and finally the first effective therapy for ASPS will be validated and then be available for all ASPS patients.

Best Wishes,
Yosef Landesman
______________________________________________________

Yosef Landesman, Ph.D.
President & Cancer Research Director
Cure Alveolar Soft Part Sarcoma International (iCureASPS)
e-mail: landesmany@yahoo.com

Happy New Year 2012!

Dear ASPS community,

iCureASPS is wishing you all Happy 2012!


We would like to thank our “Team ASPS” for the PMC bike ride. Our team has just completed another successful year of fundraiser, following their ride in August.  It is the 8th year that Team ASPS participates in the Pan-Massachusetts Challenge, a bike -a-thon that crosses Massachusetts to raise money for cancer research and clinical trials at the Dana Farber Cancer Institute in Boston.


This year Team ASPS raised $27, 550 , funds that are restricted for research on Alveolar Soft Part Sarcoma at the Dana Farber. We selected to use these funds to support the research done by Dr. Ewa Sicinska with Dr. George Demetri and Dr. Massimo Loda.


In 2012 Team ASPS will continue its efforts to support the same initiative and I encourage you to join Team ASPS and help us to increase the support for this important research on ASPS.


Please contact me to discuss ways on how you can be part of the efforts to find a cure for ASPS.


Happy New Year and Best Wishes,


Yosef Landesman
______________________________________________________


Yosef Landesman, Ph.D.
President & Cancer Research Director
Cure Alveolar Soft Part Sarcoma International (iCureASPS)
e-mail: landesmany@yahoo.com

Update on the Cediranib and Sunitinib Clinical Trials for Alveolar Soft Part Sarcoma Phase II in the USA

  Please note the two Phase II clinical trials available for ASPS patients in the US:

1.   Sunitinib or Cediranib for Alveolar Soft Part Sarcoma, study number NCT01391962

Contact: NCI Referral Office, Tel.   1-888-NCI-1937

Locations:

United States, California
Santa Monica Oncology Center
Santa Monica, California, United States, 90403

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892

United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115

United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030-4096

2.   Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma, study number NCT00942877

Contact:

Agnes T. Strassberger, R.N.    Tel.  (301) 435-5664,   e-mail:  agnes.strassberger@nih.gov

Location:

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892

______________________________________________________

Yosef Landesman, Ph.D.
President & Cancer Research Director
Cure Alveolar Soft Part Sarcoma International (iCureASPS)
e-mail:
landesmany@yahoo.com

 

New Clinical Trial for Alveolar Soft Part Sarcoma in the United Kingdom: CASPS – A Phase II Trial of Cediranib

Dear ASPS Community,

We are very happy to report the opening of another clinical trial for ASPS patients in the United Kingdom. This new clinical trial is a phase II trial of Cediranib. Every trial brings with it the hope for cure!

ASPS patients who are trying Cediranib are sharing their experience on iCureASPS Forum. I would encourage everyone to click here and read comments and discussions of those patients. Please use our website, read and study well! Share information and communicate.

Best Wishes to everyone and thank you very much Dr. Judson and all who are working with you for taking the lead on this clinical trial.

Yosef Landesman, Ph.D.

President & Cancer Research Director

e-mail: landesmany@yahoo.com

__________________________________________

CASPS – A Phase II Trial of Cediranib in the Treatment of Patients with Alveolar Soft Part Sarcoma

Sponsored by: The Institute of Cancer Research / The Royal Marsden NHS Foundation Trust

Information provided by: The Institute of Cancer Research – Clinical Trials and Statistics Unit

ClinicalTrials.gov Identifier: NCT01337401

Cediranib (AZD2171) is a new, unlicensed drug that has been studied in the laboratory and clinic, and researchers think it could slow the spread of ASPS. CASPS is a small clinical trial investigating cediranib in the treatment of ASPS, which is currently open to recruitment in the UK. Further information on CASPS and a list of hospitals involved in the trial can be found at:

http://cancerhelp.cancerresearchuk.org/trials/a-trial-cediranib-alveolar-soft-part-sarcoma-casps.

Objective: The aim of this study is to see if cediranib (AZD2171) can help people with alveolar soft part sarcoma.

Eligibility: Individuals 16 years of age and older who have been diagnosed with alveolar soft part sarcoma. Please note that other eligibility criteria do apply – for further details please go to:

http://cancerhelp.cancerresearchuk.org/trials/a-trial-cediranib-alveolar-soft-part-sarcoma-casps.

Contact: Professor Ian Judson, casps-icrctsu@icr.ac.uk

Locations: United Kingdom